RMD ResMed Inc.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About ResMed (NYSE: RMD)
›
ResMed (NYSE: RMD) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 11,370 employees.
The shares were at 236.88 USD on 19 November 2026, down 2.6% over 52 weeks. Its 52-week range is 180.26 USD to 277.67 USD: the price is 14.7% below the high and 31.4% above the low.
At a market capitalisation of 33.32B USD, it trades at 21.6 times trailing earnings and 17.9 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 51.8, a discount of 58% for RMD. It pays a dividend yielding 1.09% (it pays out 22% of its earnings), against a median of 0.48% among the dividend payers in that peer group.
ResMed reports return on equity of 23.1%, an operating margin of 34.0% and revenue up 5.9% year over year.
It holds more cash than debt, a net cash position of 400.16M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 264.33 USD is 11.6% above the current price. The next earnings report is expected on 28 January 2027.